Long-Term Clinical Practice Experience with Cinacalcet for Treatment of Hypercalcemic Hyperparathyroidism after Kidney Transplantation

Figure 4

Parathyroid hormone levels in kidney transplant recipients treated with cinacalcet for hypercalcemic hyperparathyroidism. Variations of intact parathyroid hormone levels before and after initiation of cinacalcet () are plotted over time. Starting point of the pretreatment period is the date when the patients initially presented with hypercalcemia following transplantation. For both pre- and posttreatment period, quarterly median values were obtained for each patient by summarizing all repeated measurements over a three-month period starting from . Values were excluded if a patient received active vitamin D in addition to cinacalcet. Data are presented as medians and interquartile ranges.